McMurry-Heath Michelle 4

What Happened

• Michelle McMurry-Heath, a director of Bioventus, sold 12,000 shares in open-market transactions on March 11, 2026. The filing reports a weighted average sale price of $8.79, resulting in proceeds of approximately $105,439. This was a sale (not a purchase or option exercise).

Key Details

• Transaction date: 2026-03-11; Form 4 filed: 2026-03-13 (filed within the typical 2-business-day window).
• Reported weighted average price: $8.79; total proceeds: $105,439.
• Footnote: the sale occurred in multiple transactions at prices ranging from $8.73 to $8.81. The reporting person will provide a per-price breakdown on request (Footnote F1).
• Shares owned after the transaction: not disclosed in the provided excerpt.
• No 10b5-1 plan, tax-withholding, gift, or option-exercise notation was reported in the provided details.

Context

• Sales by directors are common and can reflect personal liquidity needs or portfolio rebalancing; they are generally less definitive about company prospects than purchases. This report is a straightforward open-market sale and does not, by itself, indicate insider expectations about Bioventus’s future performance.